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patternWe published a paper on September 13, 2005 in
the International Journal of Surgery that discussed
our research in breast cancer.1 As our work provided
a new perspective and possible explanation of
a subject steeped in controversy for a decade,
the Journal issued a press release, as did the
home institution of the lead author. This was widely
reported in the medical and lay press including
interviews and comments from one or more of
the authors and, for balance in reporting, contrary
views from scientists or physicians were often
included (see Table 1). We want to take this oppor-
tunity to discuss the resulting favourable and
unfavourable comments including the letters to
the editor published in this issue of the IJS and
to provide our own comments on this episode.
Much of the criticisms state that our paper does
not prove its case. This is a very important issue as
it involves the quality of the discussion from two
points: the logic of our arguments and the level of
understanding of these by the discussant. As for
the first point, we believe that we should not be
‘‘interpreted’’ and that only our stated remarks
should be attributed to us. We never argued that
we were providing some ‘‘proof’’ of something.
Our paper simply suggests a possible biology-based
explanation of clinical observations, and no state-
ments about ‘‘proven hypotheses’’ were reported.1743-9191/$ - see front matter ª 2005 Surgical Associates Ltd. Pu
doi:10.1016/j.ijsu.2005.10.017Regarding the second point, we never tire of
repeating what all researchers know:
It is virtually impossible to prove that a given
model is true, models can only be disproved
when they result in significant departure from
observed findings.
We wish to affirm here that if our explanation
will be proven unfounded (this might be done), we
will reject it and we will accept a better one. This
is the way by which science moves forward.
Critics frequently noted that breast cancer in
young women is more aggressive and that is prob-
ably the reason for the early relapses amongwomen
aged 40e49 years. The point is not to deny that this
‘‘aggressiveness’’ occurs, the point is ‘‘Why?’’ And
‘‘Why premenopausal women?’’. We suggested2e6
that ‘‘aggressiveness’’ is the putative result of sur-
gery induced angiogenesis. Since 20% of young
women with node-positive disease would relapse
within one year of surgery in absence of chemother-
apy, that is certainly an expression of aggressive
behaviour. We suggest that this is ordinary tumour
growth but kick-started out of dormancy by sur-
gery. Furthermore we suggested that it happens
among premenopausal women because of their
hormone milieu4,5 and that a further factor may
play a role i.e., timing of surgery in the menstrualblished by Elsevier Ltd. All rights reserved.
236 EditorialTable 1 A table of the responses from researchers and clinicians published in the media
Person commenting Publication/source Their comments and authors reply (in italics)
Michael O’Reilly, MD
Anderson Centre,
Texas, USA
Wall Street Journal,
13 September 2005
.animal data suggest that surgery-induced angiogenesis exists,
and could be a factor in early relapse. But it still wasn’t clear
whether the phenomenon worked the same way in every cancer,
how to identify at-risk patients, or even whether surgery-induced
angiogenesis was the only explanation. ‘‘It may explain the
phenomenon in some patients but not all of them,’’ (These points
are well taken. Dr. O’Reilly was lead author of the Cell 1994
paper documenting surgery induced angiogenesis in the Lewis
lung model.)
Robert Smith,
American
Cancer Society
WebMD Health,
13 September 2005
Don’t believe any of this. The idea that surgical interruption of
the tumor bed will cause death this rapidly just does not make
sense. The idea that women became worse after surgery may
stem from the fact that their prognosis may have been poorer to
start with since young women tend to get more aggressive
cancers. Retsky et al. misread the trial data. Retsky et al.’s data
are based on observations from long ago, when breast cancer
screening was in its infancy. (In the editorial, we address some of
the issues raised by Drs. Smith, Kopans, Borgen and Love.)
Daniel Kopans,
Massachusetts
General Hospital,
USA
Boston Globe,
13 September 2005
If we discourage women from getting breast cancer screening,
significant gains that we have made will go down the tubes. (and
from Wall Street Journal). The number of cases. are too small
to permit accurate analysis.
Patrick Borgen,
Memorial Sloan
Kettering Cancer
Center, USA
Boston Globe,
13 September 2005
The study is mostly theory and hypotheses that could scare
people from getting mammograms out of fear that the treatment
will kill them.
Susan Love, Dr. Susan
Love Research
Foundation, USA
SusanLoveMD.org,
http://www.
susanlovemd.com/
community/flashes/
news091305.htm
‘‘The idea that surgery could cause cancer to spread originated in
animal studies that were first conducted about 15 years ago.
Some of these studies suggested that cancer cells that have
metastasized . could begin to grow once the primary tumor is
removed. Others suggested that surgery might even cause the
spread of cancer. But what is true in animals is not always true in
humans.’’
‘‘.it’s impossible to say that the surgery itself was responsible for
the recurrence and not some other factor, such as the timing of the
surgery, hormone levels, if mammography detected the cancer, or
whether treatment included chemotherapy and/or radiation.
Also, it is well recognized that young women tend to have tumors
with more aggressive characteristics than those that appear in
older women, which could influence the findings as well..it is
very critical that news stories make it clear that this particular
study is pure conjecture. The last thing that I would want to hear is
that women are not getting surgery to remove breast cancer
tumors because they are afraid the surgery will cause the cancer to
spread.’’
Blogosphere Book of Joe, 13
September 2005,
http://www.
bookofjoe.
com/2005/09/
behindthemedspe_
9.html
.one of the most explosive and controversial papers to appear in
the medical literature in recent years .
Hazel Thornton,
University of
Leicester, UK
Editorial in this
issue of the IJS
Letter questions decision making process and the advisability of
issuing a press release (We address these serious and valid
questions below).
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Person commenting Publication/source Their comments and authors reply (in italics)
Don Berry, MD
Anderson Centre,
Texas, USA
See correspondence
section
Paper is plausible but data could also be explained by the
heterogeneity of breast cancer. (Biostatistician Dr. Berry has
published papers in this field and testified to US Congress on the
mammography controversy. We propose that part of that black
box of heterogeneity is a predictable negative effect of early
interaction in a subset of node positive premenopausal women.)
Tom Marshall,
University of
Birmingham, UK
See correspondence
section
Need to address the Bradford Hill criteria for causation (In the
editorial, we address consistency and experimental evidence e
two of the most pertinent of the nine Bradford Hill criteria.)
Isaac Gukas,
Oncologist, Nigeria
See correspondence
section
Nigerian data are discussed (We would be interested in examining
these data and comparing to the Milan database.)
Gail Washington,
FedEx executive,
USA
See correspondence
section
Discussion of some AfricaneAmericans’ common acceptance of
the popular ‘‘myth’’ that cancer spreads when air hits it (We
agree that surgery induced angiogenesis would have all the
appearances of this often-heard expression.)
Susan Clare, Indiana
University, USA
See correspondence
section
This letter discusses an innovative biological state of dormant
cells (As with Dr. Clare, we are also interested in how to improve
therapy outcome. We think that current adjuvant therapies are
mainly directed toward delaying or curing patients who would
have relapsed in the first peak. Questions arise such as why these
therapies are not more effective [as Dr. Clare mentioned], how
can we better treat patients destined to relapse in the second
peak and how do these depend on surgery [including induced
tumor growth] following early or late detection.)
P. Sooriakumaran,
Royal Surrey
County Hospital, UK
See correspondence
section
Discusses possible relevance to prostate (There is much to learn
from comparisons of clinical cancer behaviour in different
organs. It is especially interesting that there is also an age effect
in prostate cancer.)cycle might modulate the tumourehost relation-
ship and ultimately the disease outcome.7e9 In other
words, we suggested a biology-based conceptual
model by applying to women some facts and mech-
anisms incontrovertibly demonstrated in animal
models, such as tumour dormancy,10e15 surgery-
driven tumour growth acceleration,16e19 and angio-
genesis linked to sex hormone correlations.20 Even
if humans are not mice and we are well aware
that what is true in animals is not always true in
humans, we are definitely persuaded that we share
most of our biology with other mammals and that,
as ‘‘Natura non facit saltus’’, it is perfectly justified
to do this. Obviously, confirmatory data should be
looked for and found in breast cancer patients. Any-
way, corroboration of the general correctness of
our hypotheses is to be seen inmany recent publica-
tions. For example, persistency of breast cancer
cells in bone marrow21 or in blood22 months and
even years following primary tumour surgical
removal have been documented. Angio-active mol-
ecules have been observed to wax and wane within
each menstrual or estral cycle.23e25 Moreover, the
failure of continuous growth to explain clinical find-
ings, such as breast cancer local recurrences, andthe need to assume some tumour growth interrup-
tion, were confirmed a few years ago.26
About the possible explanation of the mammog-
raphy screening paradox in younger women that
we proposed, the first point is the occurrence of
the phenomenon. Some have denied the occur-
rence of an early mortality excess for younger
women and suggest that it represents a statistically
insignificant artefact. We do not have a fidelistic
attitude towards the p-value from either univari-
ate or multivariate analysis but wish to emphasize
the fact that the early mortality excess of invited
women is documented consistently across screen-
ing trials, countries and time, supports its clinical
and scientific significance. The second point is to
agree that the surge in mortality at the third
year is very difficult to explain if tumours are au-
tonomous, even by recourse to the heterogeneity
of breast cancer. We state that it would not be
possible unless something synchronized screened
young women and initiated sudden tumour growth.
Our study of the Milan breast cancer database
strongly suggested that something near the time of
surgery induced angiogenesis in 20% of premeno-
pausal womenwith node positive disease. With that
238 Editorialassumption, we were able to calculate the result of
this in a trial of early detection of breast cancer.
That turned out to be 0.1 deaths per 1000 screened
young women in the third year. That is the same
value that is seen in the trials. This would be
a temporary effect (concerning the trials e obvi-
ously not the affected individuals) and eventually it
would appear that screening reduced mortality.
This is also seen in the trials. We were very im-
pressedwith themeta-analysis data fromCox27 that
were based on over 800,000 person-years of experi-
ence in both the intervention arm and the control
arm. We called this indirect evidence but, based
on our findings, that was a conservative statement
and we think far stronger than pure conjecture.
Most criticisms came from physicians involved in
mammography screening, who stigmatized any
idea of reconsidering screening guidelines for
young women by stating that the paper will
frighten young women into avoiding mammography
or, from bad to worse, into avoiding surgery to
remove breast cancer. In the paper, we called for
the reconsideration of guidelines for early
detection of breast cancer and suggested that, at
the very least, women need to be advised of the
information presented. Obviously, we were not
addressing this to lay persons but to specialists and
we are very surprised at their foreclosure of any
possible doubt about a subject that in the past had
such a wavering course.
To reconsider does not mean to change, but
only to take into account some other point to
verify whether we are doing the right thing. In our
opinion, as each man and woman is landlord of his
or her own life, he or she is entitled to have all
relevant elements to make decisions. The majority
report and the minority report of the 1997 NIH
Consensus Conference strongly disagreed on the
key recommendations but both agreed that women
needed to be advised of the risks and benefits of
early detection. Anyway, after seeing the wide-
spread publicity occurring, we took care to clarify
that at present we are certainly not recommending
any change in clinical practice but that this topic
needs to be readdressed on a scientific level. We
did this on our own volition. Our would-be censors
are concerned that women will not understand
these results and take inappropriate action. These
criticisms are condescending to women implying
that they are not capable of making appropriate
informed decisions. We find these criticisms to be
wrong but we are well aware of the technically
challenging discussion and emotional climate sur-
rounding this topic. However, we wonder, how
should a scientific minority behave? Should it be
silent? The minority opinion group at the 1997 NIHConsensus Conference was not. Is science a ques-
tion of votes?
It is proper to address the question of the
advisability of issuing press releases, mainly
when the press shows the trend to sensationalize
the conclusions and when errors in reporting
cannot be avoided. We published papers in the
past that discussed the possibility that surgery
could induce angiogenesis, mostly in premeno-
pausal patients with node positive disease, and
that this would explain the mammography para-
dox.4,28,29 The hypotheses are testable and the
risks of early detection can be eliminated with bet-
ter understanding and research. But first they need
to be discussed. We have been very patient waiting
for this study to be debated and have not rushed
into issuing press releases promoting our work.
One of us (MR) is a patient advocate on the Board
of Directors of the Colon Cancer Alliance. From an
advocate/researcher’s perspective, the mammog-
raphy paradox or controversy is odorous and needs
to be properly aired out in public. This was likewise
consistent with our intention to fuel a debate about
the merit of the scientific proposal. We might have
been wrong. Yet, to affirm with certainty that it has
been so, we wish to wait for the future scientific
debate among oncology researchers.
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